both the spleen and pancreas of NOD mice. In both tissues, the 2.5HIP tetramer stained a higher percentage of CD4 T cells compared with the 2.5mi and the pS3 tetramers, a difference that was statistically significant in the pancreas and that indicated that the 2.5HIP tetramer is more efficient in the detection of 2.5HIP-reactive CD4 T cells. Our data show that most of the 2.5HIP tetramer-positive cells in the spleen were CD44 high, which indicated that a significant proportion of these cells were antigen-experienced and further substantiated their involvement in the pathogenic process.
To determine whether human CD4 T cells of individuals with T1D recognize HIPs, we screened a selection of HIPs (Fig. 4A ) using CD4 T cells isolated from the residual islets of two patients. Corresponding human sequences of naturally occurring peptides found in mouse b cell extracts formed the right portion of the HIPs. The central C-peptide amino acid sequences ELGG or ELGGG, which form the left half of HIPs 1 to 8, satisfy parameters for binding to DQ8 positions 1 and 4 (14) . Risk of developing T1D is strongly associated with human leukocyte antigen (HLA) alleles, and HLA-DQ8 confers the highest risk of developing T1D of any single HLA allele (15) . For the left sides of HIPs 9 to 16, we used the human version (SLQPLAL) of the murine peptide sequence present in the 2.5 and 6.9HIPs. From one organ donor, 17 CD4 T cell lines were isolated from residual islets, expanded, and tested for reactivity against eight of the HIPs ( ) as presenters. The CD4 line MG1 responded to the HIP formed by fusion of proinsulin C-peptide to the pancreatic peptide, neuropeptide Y (GQVELGGG-SSPETLI) (Fig. 4B) . Using CD4 T cell clones isolated from a second organ donor (16) , we screened all 16 HIPs (Fig. 4A) . Two clones responded to the same HIP that was formed by the fusion of proinsulin Cpeptide to IAPP2 (GQVELGGG-NAVEVLK) (Fig. 4 , C and D). Both clones responded weakly to proinsulin C-peptide (proinsulin 37-54), but the HIP was 1000 to 10,000 times as potent. Both clones recognized HIP peptides presented by HLA-DQ8 (DQA1*03:01; DQB1*03:02) ( fig. S6 ). Although pathogenicity of human T cells cannot be directly demonstrated, the presence of HIP-specific CD4 T cells within the pancreatic islets of individuals with T1D supports the contention that these cells play a pathogenic role in human T1D.
HIPs represent not only a novel posttranslational modification in autoimmune disease, but they also constitute a new family of autoantigens in T1D. Hybrid peptides that form through protein splicing have been previously noted in tumor antigen formation, a process that occurs through the proteosomal class I pathway and yields antigens for CD8 T cells (17) (18) (19) . The formation of HIPs in the secretory granules of b cells could be a side reaction of the proteolytic hydrolysis of peptide bonds in the presence of naturally occurring cleavage products (e.g., WE14), and molecular crowding of peptides in secretory granules may favor this reversed proteolytic transpeptidation (20) . The identification of HIP-reactive CD4 T cells from the islets of individuals with T1D, together with the demonstration that several distinct pathogenic CD4 T cells from NOD mice target different HIPs in b cells, strongly suggests that HIPs play a central role in the pathogenesis of T1D. We hypothesize that HIPs are key antigens for autoreactive T cells and are responsible for the loss of self-tolerance in human T1D. We would also speculate that hybrid peptides may form in the secretory granules of other endocrine tissues and could be a source of self-antigens in other autoimmune disorders. fig. S1 ).
To understand the basis of this unusual MHC-I-dependent recognition, we selected four RMs vaccinated with the 68-1 RhCMV/SIVgag vector for detailed MHC-I restriction analysis. We first sequenced the expressed MHC-I genes, including both classical MHC-Ia and nonclassical MHC-Ib (9), in each RM, and constructed a panel of MHC-I transfectants that individually expressed these MHC-I molecules ( fig. S2 ). These single-MHC-Imolecule transfectants were then used in a flowcytometric intracellular cytokine staining (ICS) assay to present 12 commonly recognized 15-mer (15-amino acid oligomer) peptides to the CD8 + T cells induced by the 68-1 RhCMV/SIVgag vector in these RMs (Fig. 1, A S4 ). However, all 12 peptides stimulated epitope-specific CD8 + T cells when presented by nonclassical major histocompatibility complex E (MHC-E) molecules, and all peptides were presented by transfectants singly expressing three different RM MHC-E allomorphs (Mamu-E*02:04, -E*02:11, and -E*02:20), as well as by a transfectant expressing human MHC-E (HLA-E*01:03; HLA, human leukocyte antigen) (Fig. 1, A and B, and figs. S3 and S5).
MHC-E is known to avidly bind canonical VMAPRTL(LVI)L peptides, which are derived from positions 3 to 11 of MHC-Ia leader sequences, for presentation to NKG2A/C receptor molecules on natural killer (NK) cells (10) (11) (12) (13) (14) . This conserved interaction predominantly inhibits NK cell activity when cells express normal levels of MHC-Ia. However, on interference with MHC-Ia biosynthesis by viral infection or neoplastic transformation, this inhibitory signal is reduced, facilitating NK cell responses to virally infected or neoplastic cells (15, 16) . (6) . These optimal 9-mer peptides could trigger CD8 + T cells when pulsed on MHC-E transfectants (both Mamu-E and HLA-E) or autologous B cell lines at doses of ≤1 nM ( Fig. 1C  and fig. S9 ); such functional avidities are comparable to T cell recognition of classically MHC-Ia-restricted epitopes (18) . Taken together, these data strongly suggest that the unconventional, MHC-I-dependent CD8 + T cell responses elicited by the 68-1 RhCMV/ SIVgag vector reflect SIVgag 9-mer epitope-specific, MHC-E-restricted CD8ab + T cells.
MHC-E-restricted CD8
+ T cell responses previously have been identified in human cytomegalovirus (HCMV), hepatitis C virus, Mycobacterium tuberculosis (M. tb.), and Salmonella enterica infections, typically involving epitopes that are structurally related to the canonical MHC-Ia leader-sequence peptides but foreign to the host (13, 14, 19, 20) . To determine the extent to which MHC-E restricts RM CD8 + T cell responses in different settings, we applied blocking with high-affinity MHC-E-binding peptide VL9 [in conjunction with blocking with the MHC-IIassociated invariant chain peptide (CLIP) and the MHC-I monoclonal antibody (mAb) W6/32 (6)] to restriction-classify all SIVgag epitope-specific CD8 + T cell responses in RMs vaccinated with the 68-1 RhCMV/SIVgag vector (DRh157.5/.4), a strain 68-1.2 RhCMV/SIVgag vector (Rh157.5 and Rh157.4 repaired), a 68-1.2 RhCMV/SIVgag vector from which the Rh157.5 and Rh157.4 genes were specifically reexcised ( fig. S10) , and a modified vaccinia Ankara (MVA)/SIVgag vector, as well as RMs infected with SIV itself ( Fig. 2A and figs . S11 and S12). This analysis revealed that essentially all SIVgag epitope-specific CD8 + T cells in RMs vaccinated with the 68-1 RhCMV/SIVgag or DRh157.5/.4 68-1.2 RhCMV/SIVgag vectors were either MHC-II-or MHC-E-restricted. In contrast, 98 to 100% of SIVgag-specific CD8 + T cell responses in the RMs vaccinated with the MVA/SIVgag or 68-1.2 RhCMV/SIVgag vectors, or infected with SIV, were classically MHC-Ia-restricted. In keeping with these patterns of epitope restriction, recognition of autologous SIV-infected CD4 + T cells by the SIVgagspecific CD8 + T cells elicited by the 68-1 RhCMV/ SIVgag vector was completely blocked by a combination of the MHC-II-blocking CLIP and the MHC-E-blocking VL9 peptides; however, SIV-infected autologous cell recognition by the SIVgag-specific CD8 + T cells elicited by MVA/SIVgag vector vaccination, 68-1.2 RhCMV/SIVgag vector vaccination, or SIV infection was insensitive to the CLIP-plus-VL9 peptide combination (Fig. 2B ). In addition, the VL9 peptide alone completely blocked SIV-infected cell recognition by a MHC-E-restricted SIVgag 482-490 (120)-specific CD8 + T cell line ( fig. S14 ). Taken together, these data confirm that the 68-1 RhCMV/SIVgag vector elicits SIVgag-specific CD8 + T cell responses that are either MHC-II-or MHC-E-restricted, and that this unusual immunobiology is a specific consequence of the deletion of the RhCMV Rh157.5 and Rh157.4 genes, which are orthologs of the HCMV UL128 and UL130 genes and encode two components of the pentameric receptor complex involved in CMV infection of nonfibroblasts (21) . Moreover, these data confirm that although SIV infection does not efficiently prime MHC-E-restricted CD8 + T cell responses, at least some of the SIV epitopes recognized by the CD8 + T cells elicited by the 68-1 RhCMV/SIVgag vector are naturally presented by SIV-infected cells, providing for their effective recognition by these heterologous responses.
Among 42 RMs vaccinated with the 68-1 RhCMV/SIVgag vector, we identified a median of 20 distinct CD8 + T cell-recognized, MHC-Erestricted SIVgag 15-mer epitopes per RM, a breadth that exceeds the median 11 and 14.5 distinct MHC-Ia-restricted SIVgag-specific epitopes identified within SIVgag-specific CD8 + T cell responses elicited by conventional vaccines or SIV infection, respectively (Fig. 3A) . The ability of DRh157.5/.4 RhCMV vectors to elicit MHC-E-and MHC-II-restricted CD8 + T cells is not limited to SIVgag-specific responses ( fig. S13) , and the density of MHC-E-restricted epitopes (~4 independent MHC-E-restricted epitopes per 100 amino acids (Fig. 3B) . Among the same 42 RMs vaccinated with the 68-1 RhCMV/SIVgag vector, 109 of the 125 overlapping SIVgag 15-mer peptides (87%) were recognized by MHC-E-restricted CD8 + T cells in at least one RM (Fig. 3C) . Although MHC-E has been shown to bind a broader array of peptides than the canonical leader-sequence peptides (14, 22) , the extent of this epitope diversity and breadth is unexpected, especially given the limited polymorphism of MHC-E and the observation that all tested Mamu-E and HLA-E variants present all tested MHC-E-restricted epitopes (Fig. 1, B and C, and figs. S5 and S9). In keeping with this previously unrecognized MHC-E epitope diversity, sequence analysis of 11 optimal MHC-E-restricted SIVgag 9-mer epitopes showed only one epitope, the Gag 273-287 (69) supertope, with a canonical MHC-E-binding motif (methionine at position 2, leucine at position 9), whereas the other 10 optimal epitopes not only lacked this motif but manifested no statistically significant overlap with previously characterized sets of MHC-E-bound peptides (Fig.  3, D and E, and fig. S15 ) (22) . Statistical analysis of a larger group of 125 SIVgag 15-mer peptides also failed to show any enrichment for previously reported MHC-E-binding motifs (figs. S16 and S17). Despite this amino acid sequence diversity, 10 of the 11 immunologically defined optimal MHC-E-restricted SIVgag 9-mer epitopes were shown to physically associate with and stabilize MHC-E, either in an ELISA (enzyme-linked immunosorbent assay)-based HLA-E-plus-peptide refolding assay or in a single-chain MHC-E-peptide expression assay, or both (figs. S18 and S19).
These data suggest that the loading and binding of epitopic peptides to MHC-E must involve novel molecular mechanisms. To explore this possibility, we performed long-time scale, all-atom molecular dynamics simulations of canonical peptide bound and unbound forms of the solved structure of HLA-E*01:03 (23) (22) . This analysis revealed that HLA-E*01:03, but not HLA-A*02:01, preserves a relatively rigid peptide binding groove that remains open even in the absence of canonical peptide during the simulation time scales (Fig. 4, A and B) . Docking analysis further suggests that the 11 optimal MHC-E-restricted SIVgag epitopes described above can bind to both HLA-E*01:03 and Mamu-E*02:04 by adopting a similar backbone configuration as that of the canonical peptide VL9, with diverse side-chain rotamers being accommodated in the same buried positions (Fig. 4C and fig. S20 ). Further characterization using all-atom molecular dynamics simulations of HLA-E-peptide complexes revealed that the SIVgag epitopic peptides bind at slightly elevated positions in the binding groove relative to VL9, which mainly uses hydrophobic amino acid sidechain interactions to stabilize its deep positioning (Fig. 4D) direct MHC-E-peptide binding analysis (figs. S18 and S19), computationally determined binding affinities of the 11 optimal MHC-E-restricted SIVgag epitopes are lower than that of VL9 ( fig.  S21 ). However, at these elevated positions in the binding groove, epitopic peptides encounter a much more varied binding environment in terms of available polar or charged binding sites (Fig. 4E) , and charged residues appear to contribute favorably to the binding of many of these peptides to MHC-E (figs. S22 and S23). Thus, in vivo conditions such as pH, ionic strength, and/or macromolecular crowding can modulate these interactions, possibly explaining some of the differences between in vitro and intracellular MHC-E-peptide binding measurements (figs. S18 and S19). There are limits to the peptide-binding breadth of MHC-E, because not all peptides can be accommodated by MHC-E in the same conformation as the canonical peptide ( fig. S24 ). These structural analyses suggest that distinctive conformational properties of MHC-E may drive the observed epitope diversity and breadth. The open MHC-E binding groove would provide access to binding for an unusually diverse population of peptides, the side chains of which could interact with chemically varying environments at different depths within the binding groove. At the same time, the framework of the relatively rigid MHC-E binding groove would enforce a similar "canonical" backbone conformation on the bound peptides, providing a stable MHC-E-peptide complex for T cell recognition. Both HCMV and RhCMV encode proteins with a strategically embedded canonical VL9 peptide within the UL40 and Rh67 genes, respectively (24, 25) . The VL9 peptide of UL40 has been shown to be loaded onto nascent MHC-E chains by a transporter associated with antigen processing (TAP)-independent mechanism, and it therefore functions to stabilize and up-regulate MHC-E expression in HCMV-infected cells in the face of virus-mediated TAP inhibition and the profound MHC-Ia down-regulation mediated by the HCMV US2-11 gene products (15, 24) . We have demonstrated a similar function for RhCMV Rh67 (fig. S25 ). MHC-E up-regulation is therefore thought to be a key viral strategy for evading the NK cell response to virally infected cells that lack MHC-Ia expression (15, 16) . However, this evasion strategy would have the consequence of enhancing MHC-E expression in such infected cells, increasing the opportunity for loading and presentation of novel peptides to MHC-E-restricted T cells. In this regard, the canonical MHC-E-binding VL9 peptide might act as a chaperone that facilitates stable high expression of MHC-E and delivery to an endosomal compartment (26) that would facilitate peptide exchange, analogous to the invariant chain-associated CLIP peptide and MHC-II (1) . The rigid open structure of the MHC-E peptide-binding groove would be expected to facilitate peptide exchange, consistent with this putative mechanism. Also, consistent with such a peptide exchange mechanism, MHC-E peptide loading has been directly demonstrated in the M. tb. phagolysosome (27) .
CMV is not the only intracellular pathogen to up-regulate MHC-E expression. Hepatitis C virus also up-regulates MHC-E expression (28), and both HIV and SIV up-regulate MHC-E in concert with MHC-Ia down-regulation ( fig. S26) (29) . This common adaptation suggests that for these and probably other intracellular pathogens, the evolutionary pressure to up-regulate MHC-E to counter NK cell responses outweighs the potential risk of increased susceptibility to MHC-E-restricted CD8 + T cells, perhaps because MHC-E-restricted CD8 + T cells are poorly primed during infection with these agents.
The reason why MHC-E-restricted CD8 + T cell responses are such a minor component of the modern mammalian immune system is unclear, especially given our finding that such responses can be diverse and broad (although arguably less diverse and broad on a population level than polymorphic MHC-Ia; fig. S27 ). However, DRh157.5/.4 RhCMV vectors are able to bypass the intrinsic constraint of MHC-E-restricted CD8 + T cell priming, perhaps by modulation of vector cell tropism and the priming microenvironment (6) . The ability of these vectors to strongly elicit broad, diverse MHC-Erestricted CD8 + T cell responses therefore offers the potential opportunity to develop vaccines that exploit MHC-E up-regulation, an intrinsic vulnerability in the immune-evasion strategies of many highly adapted persistent pathogens. Moreover, because of limited MHC-E polymorphism, a vaccine targeted at MHC-E-restricted CD8 + T cell responses would elicit largely similar responses in all or most vaccinees, potentially providing for efficacy in all individuals regardless of MHC-I genotype. Evolution may have disfavored MHC-E as a primary restricting molecule for CD8 + T cells in modern (22) were rare among our 11 optimal SIVgag peptides, whereas those that were significantly underrepresented in (22) were enriched in our SIVgag epitopic peptides, highlighted in the actual optimal epitopes listed on the right.The percentage of RMs vaccinated with 68-1 RhCMV/SIVgag (N = 42) that responded to each optimal peptide is noted as the recognition frequency.
mammals, but if HCMV vectors are able to replicate in humans the biology of DRh157.5/.4 RhCMV vectors in RMs (or, alternatively, if non-CMVbased strategies to elicit broadly targeted MHC-Erestricted CD8 + T cell responses can be developed),
vaccinologists may be able to resurrect this largely dormant MHC-E-based adaptive immune system to attack pathogens with novel immune responses that they are not adapted to effectively evade. C ells use a system of chromatin regulators (CRs) and associated histone and DNA modifications to modulate gene expression and establish long-term epigenetic memory (1) (2) (3) (4) . This system is critical in development (5), aging (6) , and disease (7) and could provide essential capabilities for synthetic biology (8) . In all of these contexts, the temporal dynamics and cell-to-cell variability of gene expression are critical but have been difficult to study, as current methods usually provide static correlations between chromatin modifications and gene expression or aggregate data across potentially heterogeneous cell populations. Therefore, it has remained unclear how strongly, rapidly, and uniformly each regulator can alter gene expression, and how long these effects persist (Fig. 1A) .
To answer these questions, we combined targeted CR recruitment (9-12) with time-lapse microscopy (13) to develop a system to quantitatively track the effects of CRs on a reporter gene in individual cells. More specifically, we fused individual CRs to the reverse Tet repressor (rTetR) (14) , which binds to DNA only in the presence of doxycycline (dox), allowing us to control the timing and duration of CR recruitment upstream of a fluorescent reporter gene expressing histone 2B (H2B)-citrine (Fig. 1B) . To isolate the system from other genes, the reporter was flanked by insulators (15) and integrated on a human artificial chromosome (HAC) (16) . All constructs were stably integrated in Chinese hamster ovary (CHO)-K1 cells, a major model system for synthetic mammalian biology (see supplementary materials and methods). Each cell line constitutively coexpressed H2B-mCherry, thus allowing cell tracking even when the reporter was silenced (Fig. 1, B and C) . Control experiments indicated that recruitment of rTetR alone does not repress reporter expression ( fig. S1 ) and that changes in gene regulation could be detected over time scales as short as 6 hours ( fig. S2 ). Therefore, this system enables analysis of the effects of recruitment and release of each CR on gene expression in individual cells.
To compare the capabilities of distinct regulators, we selected four repressive CRs that span a broad range of chromatin modifications: embryonic ectoderm development (EED), Krüppel associated box (KRAB), DNA methyltransferase 3B (DNMT3B), and histone deacetylase 4 (HDAC4). EED functions as part of the Polycomb repressive complex 2 (PRC2), which methylates histone H3 at lysine 27 (H3K27me3) (17) . KRAB functions within >400 zinc finger transcription factors (18) , associates with other CRs that write or read H3K9me3 (19) , and is often used in genetic engineering (10, 20) . DNMT3B causes de novo methylation of cytosine-guanine dinucleotides (CpGs) (21) . HDAC4 removes acetyl groups from histones H3 and H4 (22) . All of these CRs have been shown to silence gene expression during development, and their molecular mechanisms have been dissected in diverse studies (19, (23) (24) (25) . However, their dynamic operational behaviors have not been analyzed in single cells and compared side-by-side at the same target gene.
To analyze how recruitment of each CR alters gene expression, we used time-lapse microscopy to follow silencing in individual cells after the addition of dox (Fig. 1C , movies S1 to S8, and materials and methods). Recruitment of each CR strongly and specifically silenced H2B-citrine expression (Fig. 1D and fig. S3 , B and C). Silencing occurred in an all-or-none fashion in individual cells for all four CRs (Fig. 1D) at varying times after recruitment (Fig. 1E) . During the silencing
